New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
06:15 EDTPFE, NSRGYSouth Africa tells Nestle to rebrand products for Pfizer deal, Bloomberg reports
Nestle SA (NSRGY) should rebrand products to get approval from South Africa’s antitrust authority for its planned takeover of Pfizer's (PFE) baby nutrition division, the country's Competition Commission recommended, reports Bloomberg. Reference Link
News For NSRGY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 >>
September 28, 2015
15:01 EDTPFEPfizer volatility at high end of one-year range
Subscribe for More Information
07:52 EDTPFEIIR Holdings to hold a conference
Subscribe for More Information
07:27 EDTPFEFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
September 25, 2015
16:00 EDTPFEOptions Update; September 25, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 25.09. Option volume leaders: AAPL NFLX BAC FB AU NKE PFE INTC AMZN TSLA
09:34 EDTPFEActive equity options trading on open
Active equity options trading on open: AAPL BAC FB NKE NFLX PFE AU TSLA
07:22 EDTPFEEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
07:03 EDTPFEMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information
06:48 EDTNSRGYCereal makers tweak recipes in emerging markets, WSJ says
Subscribe for More Information
05:08 EDTPFEStocks with implied volatility movement; PFE HLF
Subscribe for More Information
September 24, 2015
17:04 EDTPFEMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
07:33 EDTPFEBIND says Pfizer exercises option to obtain license for Accurin drug candidate
BIND Therapeutics (BIND) announced that Pfizer (PFE) exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement. The actively targeted Accurin is designed to impart cellular targeting capability and was engineered by BIND using one of Pfizer's proprietary kinase inhibitors and one of BIND's proprietary ligands. As a result of the option exercise, BIND will receive a $2.5 million option exercise fee from Pfizer. In parallel with exercising its first option, Pfizer informed BIND that it will not exercise its option for the second compound in the collaboration. Under terms of the original collaboration agreement, which was established in April 2013, Pfizer was granted options to obtain exclusive licenses to pursue development and commercialization of two Accurins that incorporate specified Pfizer small molecular targeted therapies. For the Accurin that has been selected, both companies will work together on preclinical research; Pfizer will have responsibility for development and commercialization, and BIND will conduct chemistry, manufacturing and control activities. In addition to the $2.5 million option exercise fee, BIND received an upfront payment of $4.0 million in 2013 and achieved a $1.0 million preclinical development milestone for the selected Accurin in December 2014. BIND has the potential to receive additional milestone payments for the selected Accurin of up to $86.0 million in aggregate upon the achievement of additional specified development and regulatory events under the Pfizer collaboration agreement. BIND may also receive additional milestone payments for the selected Accurin of up to $110 million in aggregate for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of the selected Accurin, if any.
<< 1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use